Stephen H. Sands - 22 Feb 2022 Form 4 Insider Report for Cyteir Therapeutics, Inc.

Role
Director
Signature
/s/ Andrew Gengos, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
22 Feb 2022
Net transactions value
$0
Form type
4
Filing time
24 Feb 2022, 15:53:35 UTC
Next filing
07 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CYT Stock Option (Right to Buy) Award $0 +28,300 $0.000000 28,300 22 Feb 2022 Common Stock 28,300 $5.96 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock underlying this stock option award vest as to one-third of the shares subject to the option on each of the first, second and third anniversaries of February 22, 2022, subject to the Reporting Person's continued service to the board of directors of the Company through the applicable vesting date.